|
|
|
|
||
Re: CD-19Kite published Zuma-7 results for 2L. The big news is the trial reached 5 year maturity instead of number of deaths. More than 210 of the 359 (58%) are still alive at 5 years compared to 43% in 3L Zuma-1. These were healthier patients, but CR was double (65% vs 32%) vs SOC. Treatment works better in healthier patients. This is going to drive myeloma Car-T uptake significantly if they can resolve supply issues. 1L Zuma-23 vs R-CHOP now recruiting (n=300) at MDA. Last we heard from PGEN, they had not had a clinical response in a year and the next data readout is 2024. Car-T revenue ... 2018 340m 2019 734m 2020 1.1b 2021 1.7b 2022 2.7b 2023 3.5b+ |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
53244 | Re: CD-19 | Redwood1205 | 1 | 3/21/2023 4:08:53 PM |